A research study of how safe a new medicine called NNC0519‑0130 is and to test its effect in people living with excess body weight with or without type 2 diabetes

2024-512719-28-00 Protocol NN9541-8116 Human pharmacology (Phase I) - Other Ended

Start 25 Jul 2024 · End 10 Dec 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol NN9541-8116

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 64
Countries 1
Sites 1

Obesity, Type 2 Diabetes with either overweight or obesity

Key facts

Sponsor
Novo Nordisk A/S
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trial duration
25 Jul 2024 → 10 Dec 2025
Decision date (initial)
2024-07-22
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-512719-28-00
WHO UTN
U1111-1305-5164

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Obesity, Type 2 Diabetes with either overweight or obesity

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Novo Nordisk A/S

Sponsor organisation
Novo Nordisk A/S
Address
Novo Alle 1
City
Bagsvaerd
Postcode
2880
Country
Denmark

Scientific contact point

Organisation
Novo Nordisk A/S
Contact name
EU Submission Hub

Public contact point

Organisation
Novo Nordisk A/S
Contact name
EU Submission Hub

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 64 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
PAREXEL International GmbH
N/A, Klinikum Westend Haus 31, Spandauer Damm 130, Berlin

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-07-25 2025-12-10 2024-08-07 2025-03-05

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-24 Germany Acceptable
2024-07-18
2024-07-22
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-08-12 Germany Acceptable
2024-07-18
2024-08-12
3 SUBSTANTIAL MODIFICATION SM-1 2024-08-13 Germany Acceptable 2024-09-06
4 NON SUBSTANTIAL MODIFICATION NSM-2 2024-10-21 Germany Acceptable 2024-10-21
5 SUBSTANTIAL MODIFICATION SM-2 2025-05-07 Germany Acceptable
2025-06-13
2025-06-17